Lords Mark Overview and Key Details
**Company Snapshot:** Lords Mark Industries Limited, incorporated in 1998 with headquarters in Mumbai, operates across several verticals. The CIN is U21000MH1998PTC115601 and ISIN is INEOMPLO1010. As of April 28, 2025, the last deal price was ₹102 per share, giving an implied market cap of ₹1840 Cr. The promoter holding is 94.86% while public holding is 5.14%.
**1. Business Overview:** The company operates in healthcare diagnostics through its subsidiary LordsMed, renewable energy solutions (solar panels, energy storage), e-mobility (electric 2-wheelers and charging solutions), IT & ITeS solutions via Lords Infotech, and paper and toner cartridge manufacturing. It focuses on scalable, high-growth sectors aligned with government initiatives like "Make in India," "Ayushman Bharat," and "Aatmanirbhar Bharat."
**2. Investment Rationale:** The company's rationale includes a diversified business model across high-impact sectors, expansion of healthcare sector through LordsMed (aiming for 1,500 diagnostic labs and 5,000 franchise collection centers), government partnerships being an approved vendor for Ayushman Bharat diagnostics and solar initiatives, technology integration venturing into AI-powered diagnostics platforms and cloud-based energy analytics, and plans for an IPO in 2025 to unlock value and fund aggressive expansion.
**3. Key Risks:** There are risks due to execution complexity in managing multiple verticals, high capex needs for diagnostics and EV infrastructure expansion, competition from strong incumbents in its sectors, and unlisted liquidity risk since the investor exit options are limited until an IPO.
**4. IPO Timeline & Exit Options:** The company has confirmed plans to list by FY25. Pre-IPO placements are under discussion to raise growth capital and platform-based secondary sales are available. They aspire for a valuation of ₹1,800-2,200 Cr at IPO.
**Financials (In Cr.):**
The company's revenue increased from ₹213 Cr in FY22 to ₹305 Cr in FY23 and ₹555 Cr (estimated) in FY24. EBITDA grew from ₹13.1 Cr in FY22 to ₹22.2 Cr in FY23 and ₹38 Cr (estimated) in FY24. PAT was ₹4.2 Cr in FY22, ₹4.6 Cr in FY23, and ₹11.3 Cr (estimated) in FY24. EPS was ₹4.2 in FY22, ₹0.82 in FY23, and ₹1.01 in FY24.
**Valuation Metrics:**
The implied market cap is ₹1840 Cr. The P/E Ratio (FY24) is 161.9x and the P/B Ratio is 19.62x. The book value is 5.2.
**5. UnlistedZone View:** Lords Mark Industries Ltd is building a high-potential platform across diagnostics, EV, and energy infrastructure. Its success depends on disciplined execution and sector-specific growth. It's rated as Watchlist - Accumulate on dips for a 3-5 year horizon, with a target valuation post-IPO of ₹1,800 - ₹2,200 Cr.
**6. Disclosures & Data Sources:** The information comes from company press releases, the LordsMed website, Business Standard reports, media interviews, and UnlistedZone research.
